APA

Shi Y., Su H., Song Y., Jiang W., Sun X., Qian W., Zhang W., Gao Y., Jin Z., Zhou J., Jin C., Zou L., Qiu L., Li W., Yang J., Hou M., Xiong Y., Zhou H., Du X., Wang X. & Peng B. (20210125). Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. : EBioMedicine.

Chicago

Shi Yuankai, Su Hang, Song Yongping, Jiang Wenqi, Sun Xiuhua, Qian Wenbin, Zhang Wei, Gao Yuhuan, Jin Zhengming, Zhou Jianfeng, Jin Chuan, Zou Liqun, Qiu Lugui, Li Wei, Yang Jianmin, Hou Ming, Xiong Yan, Zhou Hui, Du Xinhua, Wang Xiong and Peng Bo. 20210125. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. : EBioMedicine.

Harvard

Shi Y., Su H., Song Y., Jiang W., Sun X., Qian W., Zhang W., Gao Y., Jin Z., Zhou J., Jin C., Zou L., Qiu L., Li W., Yang J., Hou M., Xiong Y., Zhou H., Du X., Wang X. and Peng B. (20210125). Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. : EBioMedicine.

MLA

Shi Yuankai, Su Hang, Song Yongping, Jiang Wenqi, Sun Xiuhua, Qian Wenbin, Zhang Wei, Gao Yuhuan, Jin Zhengming, Zhou Jianfeng, Jin Chuan, Zou Liqun, Qiu Lugui, Li Wei, Yang Jianmin, Hou Ming, Xiong Yan, Zhou Hui, Du Xinhua, Wang Xiong and Peng Bo. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. : EBioMedicine. 20210125.